An elec­tion night bereft of an­swers quells bio­phar­ma's 'worst-case' fears — an­a­lysts

What to make of an elec­tion night that gave the coun­try a del­uge of nerves and no fi­nal an­swers? Well, if you’re a biotech or a phar­ma ex­ec­u­tive or in­vestor, you might de­cide that you got the best of both worlds, an­a­lysts sug­gest­ed Wednes­day morn­ing.

Al­though re­sults are still quite up in the air as of Wednes­day morn­ing, by most fore­casts, the pres­i­den­cy re­mained a tossup, while Re­pub­li­cans ap­pear nar­row fa­vorites to main­tain con­trol of the Sen­ate and De­moc­rats have main­tained con­trol of the House. That’s a recipe for a di­vid­ed gov­ern­ment, one un­like­ly to pass the kind of drug pric­ing leg­is­la­tion that has gained trac­tion on both par­ties, SVB Leerink’s Ge­of­frey Porges wrote.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER